Rheostat is developing treatments for neurodegenerative disease by modulation of mitophagy and autophagy. Rheostat is focusing on molecular pathways involved in clearance of toxic components such as damaged organelles or aggregated proteins because mutations in these pathways cause many neurodegenerative diseases associated with cognitive impairment. Rheostat aims to use knowledge about these clearance pathways to find and develop small molecules that can restore cellular balance for the treatment of neurodegenerative and rare diseases.
Rheostat Therapeutics has funding from Dementia Discovery Fund.
Timeline
People
Christophe J. Echeverri
Interim Head of Operations
Darby R. Schmidt
Senior Director, Head of Chemistry
J. Stefan Kaczmarek
Scientific Director
Joshua Resnick
Chair and CEO
Magdalene Moran
Principle Investigator
Nathaniel Tyler Blair
Associate Director of Biology
Further reading
Documentaries, videos and podcasts
Companies
References
Rheostat Therapeutics
Company
Related Topics
Parkinson's diseaseA synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.
DementiaBroad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning
